Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea
The American Journal of Tropical Medicine and Hygiene · 2025
DOI: 10.4269/ajtmh.24-0382 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2025. Verfasst von Joycelyn Salo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea. Hauptthemen laut MEDLINE: Diethylcarbamazine, Elephantiasis, Filarial, Ivermectin, Albendazole. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
After mass drug administration (MDA) for lymphatic filariasis, which involved a single coadministered dose of ivermectin plus diethylcarbamazine and albendazole (IDA), concerns arose regarding individuals who remained microfilaremic. This situation raised questions about the efficacy of the drugs and whether some individuals had not ingested them. In East New Britain Province, Papua New Guinea (PNG), where 81.7% of the population received IDA, 10 individuals were found to have microfilaremia 12 months after the first round of MDA in an area that had a high baseline of microfilaremia ( n = 29 microfilariae [Mf] positive pre-MDA). Of these 10 individuals, 7 reported having taken the IDA medication. When Mf detection was repeated 18 months later, all 10 individuals remained Mf positive. Additionally, three more Mf-positive household members were identified, and they also reported taking the IDA. These Mf-positive individuals were then retreated with IDA under direct observation. At 7 and/or 14 months after retreatment, all initially Mf-positive individuals, except for one, were found to be Mf free. Upon further questioning, it was revealed that all but one individual admitted to not taking the initial MDA. Thus, IDA effectively clears Mf in this region of PNG, and the persistent microfilaremia after MDA is primarily because of individuals failing to take the medications as prescribed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
- Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio.
- Veterans Affairs Medical Center, Cleveland, Ohio.
Förderung
- NCATS NIH HHS
Zitieren
APA
Salo, J., Westby, S., Wakol, R., Sanuku, N., Bun, K., Laman, M., & King, C. L. (2025). Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0382
Vancouver
Salo J, Westby S, Wakol R, Sanuku N, Bun K, Laman M, et al. Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea. The American Journal of Tropical Medicine and Hygiene. 2025. doi:10.4269/ajtmh.24-0382
BibTeX
@article{Salo2025,
author = {Salo, Joycelyn and Westby, Simon and Wakol, Ronnie and Sanuku, Nelly and Bun, Krufinta and Laman, Moses and King, Christopher L},
title = {Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2025},
doi = {10.4269/ajtmh.24-0382}
}
EUVIMED